A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men
Tekijät: Tadamura E, Iida H, Matsumoto K, Mamede M, Kubo S, Toyoda H, Shiozaki T, Mukai T, Magata Y, Konishi J
Kustantaja: ELSEVIER SCIENCE INC
Julkaisuvuosi: 2001
Journal: Journal of the American College of Cardiology
Tietokannassa oleva lehden nimi: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Lehden akronyymi: J AM COLL CARDIOL
Vuosikerta: 37
Numero: 1
Aloitussivu: 130
Lopetussivu: 136
Sivujen määrä: 7
ISSN: 0735-1097
DOI: https://doi.org/10.1016/S0735-1097(00)01043-3
Tiivistelmä
OBJECTIVES The present study was designed to compare the absolute myocardial blood flow (MBF) after intravenous dipyridamole infusion with that during dobutamine-atropine administration in normal healthy male volunteers.BACKGROUND Both safety and usefulness of dobutamine-atropine stress in myocardial perfusion imaging have been reported. However, no information exists on whether the magnitude of hyperemia achieved with dipyridamole and dobutamine-atropine is comparable.METHODS Myocardial blood flow was measured with positron emission tomography and O-15-labeled water in 20 healthy young men (23 +/- 3 years) 1) at baseline, 2) after dipyridamole infusion (0.56 mg/kg over 4 min), and 3) during dobutamine (40 mug/kg/min) and atropine (0.25 to 1.0 mg) infusion.RESULTS The MBF was significantly increased during dipyridamole infusion and during dobutamine-atropine stress compared with at rest (4.33 +/- 1.23 and 5.89 +/- 1.58 vs. 0.67 +/- 0.16 ml/min/g, respectively, p < 0.0001). Moreover, dobutamine-atropine infusion produced greater MBF compared with dipyridamole (p = 0.0011), while coronary vascular resistance did not differ significantly after dipyridamole administration and during dobutamine-atropine infusion (17.6 +/- 7.9 vs. 18.6 +/- 5.6 mm Hg/[ml/min/g], respectively).CONCLUSIONS Near maximal coronary vasodilatation caused by dipyridamole is attainable using dobutamine and atropine in young healthy volunteers. Dobutamine in conjunction with atropine is no less effective than dipyridamole in producing myocardial hyperemia. (J Am Cell Cardiol 2001;37: 130-6) (C) 2001 by the American College of Cardiology.
OBJECTIVES The present study was designed to compare the absolute myocardial blood flow (MBF) after intravenous dipyridamole infusion with that during dobutamine-atropine administration in normal healthy male volunteers.BACKGROUND Both safety and usefulness of dobutamine-atropine stress in myocardial perfusion imaging have been reported. However, no information exists on whether the magnitude of hyperemia achieved with dipyridamole and dobutamine-atropine is comparable.METHODS Myocardial blood flow was measured with positron emission tomography and O-15-labeled water in 20 healthy young men (23 +/- 3 years) 1) at baseline, 2) after dipyridamole infusion (0.56 mg/kg over 4 min), and 3) during dobutamine (40 mug/kg/min) and atropine (0.25 to 1.0 mg) infusion.RESULTS The MBF was significantly increased during dipyridamole infusion and during dobutamine-atropine stress compared with at rest (4.33 +/- 1.23 and 5.89 +/- 1.58 vs. 0.67 +/- 0.16 ml/min/g, respectively, p < 0.0001). Moreover, dobutamine-atropine infusion produced greater MBF compared with dipyridamole (p = 0.0011), while coronary vascular resistance did not differ significantly after dipyridamole administration and during dobutamine-atropine infusion (17.6 +/- 7.9 vs. 18.6 +/- 5.6 mm Hg/[ml/min/g], respectively).CONCLUSIONS Near maximal coronary vasodilatation caused by dipyridamole is attainable using dobutamine and atropine in young healthy volunteers. Dobutamine in conjunction with atropine is no less effective than dipyridamole in producing myocardial hyperemia. (J Am Cell Cardiol 2001;37: 130-6) (C) 2001 by the American College of Cardiology.
Turun yliopiston Tutkimustietojärjestelmän portaali